signal antigen recognition and T cell activation
signal costimulators enhance T cell activation, proliferation, and survival
signal cytokine induced T cell function, survival, and immune memory
Existing therapeutic approaches target specific stages to stimulate anti-cancer immune response. While demonstrating efficacy, the immune response is only partially mobilized by any individual signal. Combination therapies designed to target multiple signals have significantly enhanced efficacy, but with concomitant limitations related to systemic immune stimulation and healthy tissue toxicities.
Janux is developing an integrated drug pipeline that targets each of the stages of T cell activation. These programs combine tumor activation and crossover pharmacokinetics to prevent systemic immune stimulation and toxicities while generating optimal efficacy.
